Vaccine exposure via breast milk; This spontaneous case was reported by a physician and describes the occurrence of EXPOSURE VIA BREAST MILK (Vaccine exposure via breast milk) in a female patient of an unknown age exposed to mRNA-1273 (Moderna COVID-19 Vaccine) , while the mother received the product for COVID-19 vaccination.    MEDICAL HISTORY (Parent): 2 cycles of Femara April and May 2020.  The mother's past medical history included Ehlers-Danlos syndrome since an unknown date, Postural orthostatic tachycardia syndrome since an unknown date, Polyneuropathy since an unknown date, Sleep apnea since an unknown date, Maternal exposure during breast feeding and Maternal exposure during pregnancy. Previously administered products included for an unreported indication: ALCOHOL (1-3 drinks/week prior to conceiving). Concurrent medical conditions included Drug hypersensitivity (Forteo (teriparatide)), Food allergy, Fragrance sensitivity and Drug hypersensitivity (seminal plasma).    MEDICAL HISTORY (Patient): Family history included Dysplasia (Developmental dysplasia of the hip (maternal grandmother, maternal aunt, mother)). Concurrent medical conditions included Drug allergy (Forteo (teriparatide)), Deodorant allergy (fragrance) and Food allergy (pomegranate). Concomitant product exposures included DOXYLAMINE SUCCINATE, PYRIDOXINE HYDROCHLORIDE (BONJESTA) and ONDANSETRON for Nausea, PRENATAL MULTIVITAMIN + DHA, VITAMIN D3 and MAGNESIUM for Pregnancy, LEVOTHYROXINE from an unknown date to 15-Jul-2021 for Subacute thyroiditis and Hypothyroidism.    On an unknown date, the mother received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. The mother's last menstrual period was on 21-May-2020 and the estimated date of delivery was 24-Feb-2021. On an unknown date, the patient was diagnosed with EXPOSURE VIA BREAST MILK (Vaccine exposure via breast milk). The mother had a vaginal delivery which occurred on an unknown date, which was reported as Full-term. For neonate 1, The outcome was reported as Delivered NOS. Live, full-term birth. At the time of the report, EXPOSURE VIA BREAST MILK (Vaccine exposure via breast milk) had not resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 08-Jul-2020, Glucose tolerance test: normal (normal) normal. On 08-Jul-2020, Ultrasound abdomen: normal 7 week u/s (normal) normal 7 week u/s and normal normal ultrasounds at MFM OB every 1-2 weeks.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Transmammary) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Transmammary), the reporter did not provide any causality assessments.   Reporter reported that the patient 1-3 drinks/week prior to conceiving.  No treatment medication provided.  Company Comment: This is a spontaneous case concerning a child of unknown age and gender with the history of exposure during pregnancy and during breastfeeding and no other relevant history. No adverse events were reported. The exposure was on unknown date with the mRNA 1273 vaccine. The benefit-risk relationship of mRNA 1273 vaccine is not affected by this report.   This case was linked to MOD-2021-011577, MOD-2021-259284.   See case MOD-2021-011577,MOD-2021-259284 for details regarding the Parent case.  Most recent FOLLOW-UP information incorporated above includes: On 18-Jul-2021: Upon internal review On 17-Nov-2021 pregnancy-yes,fetal outcome, birth type, prospective Corrected.; Sender's Comments: This is a spontaneous case concerning a child of unknown age and gender with the history of exposure during pregnancy and during breastfeeding and no other relevant history. No adverse events were reported. The exposure was on unknown date with the mRNA 1273 vaccine. The benefit-risk relationship of mRNA 1273 vaccine is not affected by this report.